##gff-version 3
##sequence-region P55157 1 894
P55157	UniProtKB	Signal peptide	1	18	.	.	.	Ontology_term=ECO:0000255;evidence=ECO:0000255	
P55157	UniProtKB	Chain	19	894	.	.	.	ID=PRO_0000041593;Note=Microsomal triglyceride transfer protein large subunit	
P55157	UniProtKB	Domain	28	659	.	.	.	Note=Vitellogenin;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00557	
P55157	UniProtKB	Alternative sequence	134	151	.	.	.	ID=VSP_056325;Note=In isoform 2. EFYSYQNEAVAIENIKRG->GRLDSTTFSPTSYFSSLQ;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:15489334;Dbxref=PMID:15489334	
P55157	UniProtKB	Alternative sequence	152	894	.	.	.	ID=VSP_056326;Note=In isoform 2. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:15489334;Dbxref=PMID:15489334	
P55157	UniProtKB	Natural variant	95	95	.	.	.	ID=VAR_014016;Note=Q->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11792722;Dbxref=dbSNP:rs61733139,PMID:11792722	
P55157	UniProtKB	Natural variant	98	98	.	.	.	ID=VAR_052961;Note=E->D;Dbxref=dbSNP:rs2306986	
P55157	UniProtKB	Natural variant	128	128	.	.	.	ID=VAR_014017;Note=I->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11792722,ECO:0000269|PubMed:14732481;Dbxref=dbSNP:rs3816873,PMID:11792722,PMID:14732481	
P55157	UniProtKB	Natural variant	166	166	.	.	.	ID=VAR_052962;Note=N->S;Dbxref=dbSNP:rs3792683	
P55157	UniProtKB	Natural variant	168	168	.	.	.	ID=VAR_022658;Note=Rare polymorphism. V->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:14732481;Dbxref=dbSNP:rs61750974,PMID:14732481	
P55157	UniProtKB	Natural variant	169	169	.	.	.	ID=VAR_074553;Note=In ABL%3B no loss on localization to the endoplasmic reticulum%3B does not reduce interaction with APOB%3B inhibits interaction with P4HB/PDI%3B inhibits phospholipid or triglyceride transfer activity%3B inhibits apolipoprotein B secretion. D->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26224785;Dbxref=PMID:26224785	
P55157	UniProtKB	Natural variant	244	244	.	.	.	ID=VAR_014018;Note=Q->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11792722;Dbxref=dbSNP:rs17599091,PMID:11792722	
P55157	UniProtKB	Natural variant	264	264	.	.	.	ID=VAR_074554;Note=In ABL%3B unknown pathological significance%3B does not reduce interaction with P4HB/PDI and APOB%3B does not reduce triglyceride transfer activity. G->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25108285;Dbxref=dbSNP:rs1367079155,PMID:25108285	
P55157	UniProtKB	Natural variant	297	297	.	.	.	ID=VAR_010640;Note=Polymorphism%3B does not inhibit apolipoprotein B secretion. H->Q;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11792722,ECO:0000269|PubMed:14732481,ECO:0000269|PubMed:8939939;Dbxref=dbSNP:rs2306985,PMID:11792722,PMID:14732481,PMID:8939939	
P55157	UniProtKB	Natural variant	384	384	.	.	.	ID=VAR_010641;Note=Polymorphism%3B no loss on localization to the endoplasmic reticulum%3B does not reduce interaction with P4HB/PDI%3B reduces phospholipid or triglyceride transfer activity%3B does not inhibit apolipoprotein B secretion. D->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:23475612,ECO:0000269|PubMed:8939939;Dbxref=dbSNP:rs17029215,PMID:23475612,PMID:8939939	
P55157	UniProtKB	Natural variant	435	435	.	.	.	ID=VAR_074555;Note=In ABL%3B no loss on localization to the endoplasmic reticulum%3B inhibits triglyceride transfer activity. L->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22236406;Dbxref=PMID:22236406	
P55157	UniProtKB	Natural variant	528	528	.	.	.	ID=VAR_074556;Note=In ABL%3B does not reduce interaction with P4HB/PDI and APOB%3B inhibits triglyceride transfer activity. Y->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25108285;Dbxref=dbSNP:rs1485375137,PMID:25108285	
P55157	UniProtKB	Natural variant	540	540	.	.	.	ID=VAR_074557;Note=In ABL%3B does not reduce interaction with P4HB/PDI and APOB%3B inhibits triglyceride transfer activity. R->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25108285;Dbxref=dbSNP:rs372321643,PMID:25108285	
P55157	UniProtKB	Natural variant	540	540	.	.	.	ID=VAR_010642;Note=In ABL%3B no loss on localization to the endoplasmic reticulum%3B reduces interaction with P4HB/PDI%3B inhibits phospholipid or triglyceride transfer activity%3B inhibits apolipoprotein B secretion. R->H;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10679949,ECO:0000269|PubMed:23475612,ECO:0000269|PubMed:25108285,ECO:0000269|PubMed:8939939;Dbxref=dbSNP:rs199422220,PMID:10679949,PMID:23475612,PMID:25108285,PMID:8939939	
P55157	UniProtKB	Natural variant	590	590	.	.	.	ID=VAR_010643;Note=In ABL%3B no loss on localization to the endoplasmic reticulum%3B does not reduce interaction with P4HB/PDI%3B inhibits phospholipid or triglyceride transfer activity%3B inhibits apolipoprotein B secretion. S->I;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10679949,ECO:0000269|PubMed:23475612;Dbxref=dbSNP:rs199422222,PMID:10679949,PMID:23475612	
P55157	UniProtKB	Natural variant	649	649	.	.	.	ID=VAR_074558;Note=In ABL%3B unknown pathological significance%3B does not reduce interaction with P4HB/PDI and APOB%3B reduces triglyceride transfer activity. N->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25108285;Dbxref=PMID:25108285	
P55157	UniProtKB	Natural variant	746	746	.	.	.	ID=VAR_010644;Note=In ABL%3B no loss on localization to the endoplasmic reticulum%3B does not reduce interaction with P4HB/PDI%3B inhibits phospholipid or triglyceride transfer activity%3B inhibits apolipoprotein B secretion. G->E;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10679949,ECO:0000269|PubMed:23475612;Dbxref=dbSNP:rs767833468,PMID:10679949,PMID:23475612	
P55157	UniProtKB	Natural variant	780	780	.	.	.	ID=VAR_014019;Note=In ABL%3B no loss on localization to the endoplasmic reticulum%3B does not reduce interaction with P4HB/PDI%3B inhibits phospholipid or triglyceride transfer activity%3B inhibits apolipoprotein B secretion. N->Y;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10946006,ECO:0000269|PubMed:23475612;Dbxref=dbSNP:rs199422221,PMID:10946006,PMID:23475612	
P55157	UniProtKB	Mutagenesis	169	169	.	.	.	Note=No loss on localization to the endoplasmic reticulum and does not reduce interaction with APOB or P4HB/PDI%2C does partially reduce phospholipid or triglyceride transfer activity and apolipoprotein B secretion. D->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26224785;Dbxref=PMID:26224785	
P55157	UniProtKB	Mutagenesis	187	187	.	.	.	Note=No loss on localization to the endoplasmic reticulum and does not reduce interaction with APOB%2C but inhibits interaction with P4HB/PDI%2C phospholipid or triglyceride transfer activity and apolipoprotein B secretion. K->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26224785;Dbxref=PMID:26224785	
P55157	UniProtKB	Mutagenesis	187	187	.	.	.	Note=No loss on localization to the endoplasmic reticulum%2C does not reduce interaction with APOB or P4HB/PDI%2C partially inhibits triglyceride transfer activity%2C does not inhibit phospholipid transfer activity and apolipoprotein B secretion. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26224785;Dbxref=PMID:26224785	
P55157	UniProtKB	Mutagenesis	189	189	.	.	.	Note=No loss on localization to the endoplasmic reticulum and does not reduce interaction with APOB%2C but inhibits interaction with P4HB/PDI%2C phospholipid or triglyceride transfer activity and apolipoprotein B secretion. K->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26224785;Dbxref=PMID:26224785	
P55157	UniProtKB	Mutagenesis	189	189	.	.	.	Note=No loss on localization to the endoplasmic reticulum%2C does not reduce interaction with APOB or P4HB/PDI%2C partially inhibits triglyceride transfer activity%2C does not inhibit phospholipid transfer activity and apolipoprotein B secretion. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26224785;Dbxref=PMID:26224785	
P55157	UniProtKB	Mutagenesis	435	435	.	.	.	Note=No loss on localization to the endoplasmic reticulum. Inhibits triglyceride transfer activity. L->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22236406;Dbxref=PMID:22236406	
P55157	UniProtKB	Mutagenesis	435	435	.	.	.	Note=No loss on localization to the endoplasmic reticulum. Does not inhibit triglyceride transfer activity. L->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22236406;Dbxref=PMID:22236406	
P55157	UniProtKB	Mutagenesis	528	528	.	.	.	Note=Does not inhibit triglyceride transfer activity. Y->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25108285;Dbxref=PMID:25108285	
P55157	UniProtKB	Mutagenesis	528	528	.	.	.	Note=Inhibits triglyceride transfer activity. Y->K;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25108285;Dbxref=PMID:25108285	
P55157	UniProtKB	Mutagenesis	540	540	.	.	.	Note=Strongly reduces triglyceride transfer activity. R->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25108285;Dbxref=PMID:25108285	
P55157	UniProtKB	Mutagenesis	540	540	.	.	.	Note=Does not inhibit triglyceride transfer activity and apolipoprotein B secretion. R->K;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:25108285,ECO:0000269|PubMed:8939939;Dbxref=PMID:25108285,PMID:8939939	
P55157	UniProtKB	Mutagenesis	878	878	.	.	.	Note=Inhibits triglyceride transfer activity. C->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:8533758;Dbxref=PMID:8533758	
P55157	UniProtKB	Sequence conflict	585	585	.	.	.	Note=F->L;Ontology_term=ECO:0000305;evidence=ECO:0000305	
